Pharmaceutical

AbbVie’s RINVOQ now indicated for paediatric arthritis in US

AbbVie's RINVOQ is now indicated for polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) in paediatric patients.

Jun 6, 2024 - 04:00
AbbVie’s RINVOQ now indicated for paediatric arthritis in US
AbbVie's RINVOQ is now indicated for polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA) in paediatric patients.
Read the original article

Tags:

Previous Article

MDMA therapy wait goes on as FDA panel rejects Lykos’ PTSD treatment

Next Article

J&J seeks expanded approvals for paediatric HIV-1 therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk invests $4.1bn in manufacturing facility in NC

Novo Nordisk invests $4.1bn in manufacturing facility i...

Jun 26, 2024

How orphan designated drugs private equity performed in the pharmaceutical industry in Q2 2023

How orphan designated drugs private equity performed in...

Jul 21, 2023

AWT-020 by Anwita Biosciences for Sarcomas: Likelihood ...

Dec 26, 2023